124 related articles for article (PubMed ID: 1361777)
1. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD.
Selgas R; Cuesta MV; Riñon C; Romero JR; de Alvaro F; Bajo MA; Sanchez-Sicilia L
Adv Perit Dial; 1992; 8():160-5. PubMed ID: 1361777
[TBL] [Abstract][Full Text] [Related]
2. Effects of recombinant human erythropoietin on fibrinolytic system in children on continuous ambulatory peritoneal dialysis.
Gündüz Z; Kisaarslan FA; Düsünsel R; Poyrazoglu HM; Saraymen R; Per H
Adv Perit Dial; 1999; 15():278-82. PubMed ID: 10682118
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tisseel on expression of tissue plasminogen activator and plasminogen activator inhibitor-1.
Diamond MP; Kruger M; Saed GM
Fertil Steril; 2004 Jun; 81(6):1657-64. PubMed ID: 15193491
[TBL] [Abstract][Full Text] [Related]
4. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
5. [Studies on the mechanism of hyperfibrinolysis in liver cirrhosis--changes of plasma t-PA, PAI-1 and active PAI-1 levels in liver cirrhosis].
Matsuura R; Soma M; Maeda Y; Kasakura S
Rinsho Byori; 1995 Dec; 43(12):1256-60. PubMed ID: 8569037
[TBL] [Abstract][Full Text] [Related]
6. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.
Asselbergs FW; Williams SM; Hebert PR; Coffey CS; Hillege HL; Navis G; Vaughan DE; van Gilst WH; Moore JH
Thromb Haemost; 2006 Oct; 96(4):471-7. PubMed ID: 17003924
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
8. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
9. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease.
Philips M; Juul AG; Selmer J; Lind B; Thorsen S
Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392
[TBL] [Abstract][Full Text] [Related]
10. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
[TBL] [Abstract][Full Text] [Related]
11. Time to reconsider saline as the ideal rinsing solution during abdominal surgery.
Połubinska A; Winckiewicz M; Staniszewski R; Breborowicz A; Oreopoulos DG
Am J Surg; 2006 Sep; 192(3):281-5. PubMed ID: 16920418
[TBL] [Abstract][Full Text] [Related]
12. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-1 and peritoneal transport in peritoneal dialysis patients.
Wadhwa NK; Lin JJ; Parton L; Bereket G; Cabralda T; Suh H
Adv Perit Dial; 1996; 12():33-8. PubMed ID: 8865868
[TBL] [Abstract][Full Text] [Related]
14. [Tissue plasminogen activator antigen (t-PA Ag) and tissue plasminogen activator inhibitor (PAI-1) in the course of hemodialysis in patients with chronic renal failure].
Piatkowska M; Kotschy M; Nartowicz E; Rajewski W
Pol Merkur Lekarski; 1997 Jan; 2(9):205-7. PubMed ID: 10907030
[TBL] [Abstract][Full Text] [Related]
15. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 and peritoneal transport in diabetic and non-diabetic peritoneal dialysis patients.
Lin JJ; Parton L; Bereket G; Wadhwa NK
Clin Nephrol; 1995 Nov; 44(5):310-5. PubMed ID: 8605711
[TBL] [Abstract][Full Text] [Related]
17. Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Asselbergs FW; Pattin K; Snieder H; Hillege HL; van Gilst WH; Moore JH
Semin Thromb Hemost; 2008 Sep; 34(6):562-8. PubMed ID: 19085655
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the pro-thrombotic state in CAPD patients.
Preloznik Zupan I; Sabovic M; Salobir B; Buturovic Ponikvar J
Ren Fail; 2008; 30(6):597-602. PubMed ID: 18661409
[TBL] [Abstract][Full Text] [Related]
19. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon.
Martin-Malo A; Velasco F; Rojas R; Castillo D; Rodriguez M; Torres A; Aljama P
Kidney Int Suppl; 1993 Jun; 41():S213-6. PubMed ID: 8320924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]